These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 33312196)

  • 21. Planned drug holidays during treatment with lenvatinib for radioiodine-refractory differentiated thyroid cancer: a retrospective study.
    Matsuyama C; Enokida T; Ueda Y; Suzuki S; Fujisawa T; Ito K; Okano S; Tahara M
    Front Oncol; 2023; 13():1139659. PubMed ID: 37886165
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Response to Lenvatinib in Children with Papillary Thyroid Carcinoma.
    Mahajan P; Dawrant J; Kheradpour A; Quintanilla NM; Lopez ME; Orth RC; Athanassaki I; Venkatramani R
    Thyroid; 2018 Nov; 28(11):1450-1454. PubMed ID: 30226445
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prevalence and Risk Factors of Developing Fistula or Organ Perforation in Patients Treated with Lenvatinib for Radioiodine-Refractory Thyroid Cancer.
    Valerio L; Giani C; Agate L; Molinaro E; Viola D; Bottici V; Matrone A; Puleo L; Lorusso L; Cappagli V; Ribechini A; Elisei R
    Eur Thyroid J; 2021 Jul; 10(5):399-407. PubMed ID: 34540710
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy and Limitations of Lenvatinib Therapy for Radioiodine-Refractory Differentiated Thyroid Cancer: Real-World Experiences.
    Masaki C; Sugino K; Saito N; Akaishi J; Hames KY; Tomoda C; Suzuki A; Matsuzu K; Uruno T; Ohkuwa K; Kitagawa W; Nagahama M; Ito K
    Thyroid; 2020 Feb; 30(2):214-221. PubMed ID: 31854270
    [No Abstract]   [Full Text] [Related]  

  • 25. A Phase II study of the safety and efficacy of lenvatinib in patients with advanced thyroid cancer.
    Takahashi S; Kiyota N; Yamazaki T; Chayahara N; Nakano K; Inagaki L; Toda K; Enokida T; Minami H; Imamura Y; Fukuda N; Sasaki T; Suzuki T; Ikezawa H; Dutcus CE; Tahara M
    Future Oncol; 2019 Mar; 15(7):717-726. PubMed ID: 30638399
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Lenvatinib versus placebo in radioiodine-refractory thyroid cancer.
    Schlumberger M; Tahara M; Wirth LJ; Robinson B; Brose MS; Elisei R; Habra MA; Newbold K; Shah MH; Hoff AO; Gianoukakis AG; Kiyota N; Taylor MH; Kim SB; Krzyzanowska MK; Dutcus CE; de las Heras B; Zhu J; Sherman SI
    N Engl J Med; 2015 Feb; 372(7):621-30. PubMed ID: 25671254
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Safety and Effectiveness of Lenvatinib in Patients with Unresectable Hepatocellular Carcinoma in Real-World Clinical Practice: An Observational Post-Marketing Study in Japan.
    Furuse J; Izumi N; Motomura K; Inaba Y; Katamura Y; Kondo Y; Yabushita K; Motoyoshi K; Kudo M
    Drugs Real World Outcomes; 2023 Jun; 10(2):195-205. PubMed ID: 36602748
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Lenvatinib and other tyrosine kinase inhibitors for the treatment of radioiodine refractory, advanced, and progressive thyroid cancer.
    Lorusso L; Pieruzzi L; Biagini A; Sabini E; Valerio L; Giani C; Passannanti P; Pontillo-Contillo B; Battaglia V; Mazzeo S; Molinaro E; Elisei R
    Onco Targets Ther; 2016; 9():6467-6477. PubMed ID: 27799794
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effectiveness and safety of lenvatinib in a series of advanced well-differentiated thyroid carcinomas from a single tertiary cancer center and literature review.
    Damásio IL; Figueiredo A; Maciel J; Horta M; Silva TN; Simões-Pereira J; Donato S; Leite V
    Minerva Endocrinol (Torino); 2024 Mar; ():. PubMed ID: 38512702
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Phase I/II study of single-agent lenvatinib in children and adolescents with refractory or relapsed solid malignancies and young adults with osteosarcoma (ITCC-050)
    Gaspar N; Campbell-Hewson Q; Gallego Melcon S; Locatelli F; Venkatramani R; Hecker-Nolting S; Gambart M; Bautista F; Thebaud E; Aerts I; Morland B; Rossig C; Canete Nieto A; Longhi A; Lervat C; Entz-Werle N; Strauss SJ; Marec-Berard P; Okpara CE; He C; Dutta L; Casanova M
    ESMO Open; 2021 Oct; 6(5):100250. PubMed ID: 34562750
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Lesion-Based Evaluation Predicts Treatment Response to Lenvatinib for Radioactive Iodine-Refractory Differentiated Thyroid Cancer: A Korean Multicenter Retrospective Study.
    Lee EK; Kim SM; Kim BH; Kim MJ; Lim DJ; Kim MH; Shin DY; Kang HC; Ahn BC; Kim SW; Ahn HY; Park YJ
    Thyroid; 2019 Dec; 29(12):1811-1819. PubMed ID: 31482759
    [No Abstract]   [Full Text] [Related]  

  • 32. Safety of Tyrosine Kinase Inhibitors in Patients With Differentiated Thyroid Cancer: Real-World Use of Lenvatinib and Sorafenib in Korea.
    Kim SY; Kim SM; Chang H; Kim BW; Lee YS; Chang HS; Park CS
    Front Endocrinol (Lausanne); 2019; 10():384. PubMed ID: 31244783
    [No Abstract]   [Full Text] [Related]  

  • 33. OPTIMIZING LENVATINIB THERAPY IN PATIENTS WITH METASTATIC RADIOACTIVE IODINE-RESISTANT DIFFERENTIATED THYROID CANCERS.
    Jasim S; Iniguez-Ariza NM; Hilger CR; Chintakuntlawar AV; Ryder MM; Morris JC; Bible KC
    Endocr Pract; 2017 Oct; 23(10):1254-1261. PubMed ID: 28816536
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Sorafenib in metastatic radioactive iodine-refractory differentiated thyroid cancer: A pilot study.
    Luo Y; Shi Y; Xing P; Wang L; Feng Y; Han X; He X
    Mol Clin Oncol; 2014 Jan; 2(1):87-92. PubMed ID: 24649313
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Tertiary Care Experience of Sorafenib in the Treatment of Progressive Radioiodine-Refractory Differentiated Thyroid Carcinoma: A Korean Multicenter Study.
    Kim M; Kim TH; Shin DY; Lim DJ; Kim EY; Kim WB; Chung JH; Shong YK; Kim BH; Kim WG;
    Thyroid; 2018 Mar; 28(3):340-348. PubMed ID: 29350109
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Safety and Effectiveness of Lenvatinib in 594 Patients with Unresectable Thyroid Cancer in an All-Case Post-Marketing Observational Study in Japan.
    Takahashi S; Tahara M; Ito K; Tori M; Kiyota N; Yoshida K; Sakata Y; Yoshida A
    Adv Ther; 2020 Sep; 37(9):3850-3862. PubMed ID: 32676927
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Lenvatinib Therapy for Advanced Thyroid Cancer: Real-Life Data on Safety, Efficacy, and Some Rare Side Effects.
    Hamidi S; Boucher A; Lemieux B; Rondeau G; Lebœuf R; Ste-Marie LG; Le XK; Mircescu H
    J Endocr Soc; 2022 Jun; 6(6):bvac048. PubMed ID: 35475024
    [TBL] [Abstract][Full Text] [Related]  

  • 38. FDA Supplemental Approval Summary: Lenvatinib for the Treatment of Unresectable Hepatocellular Carcinoma.
    Nair A; Reece K; Donoghue MB; Yuan WV; Rodriguez L; Keegan P; Pazdur R
    Oncologist; 2021 Mar; 26(3):e484-e491. PubMed ID: 33044793
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Phase 2 study of lenvatinib in patients with advanced hepatocellular carcinoma.
    Ikeda K; Kudo M; Kawazoe S; Osaki Y; Ikeda M; Okusaka T; Tamai T; Suzuki T; Hisai T; Hayato S; Okita K; Kumada H
    J Gastroenterol; 2017 Apr; 52(4):512-519. PubMed ID: 27704266
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Lenvatinib as first-line treatment for advanced thyroid cancer: long progression-free survival.
    De Leo S; Di Stefano M; Persani L; Fugazzola L; Colombo C
    Endocrine; 2021 May; 72(2):462-469. PubMed ID: 32885329
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.